SGD Pharma, a glass pharmaceutical packaging specialist, has published its latest 2023 Corporate Social Responsibility (CSR) report.
The newly published 2023 report details the company’s endeavours that aim to improve their sustainability, and focuses on people, impact and values.
The Report follows SGD Pharma’s recent 2024 Gold EcoVadis rating, which stood at 78; a result that puts the company in the 98th percentile for manufacturers of glass products.
Even more recently, SGD Pharma has earned the Climate Action Award by PAI Partners among all of PAI’s portfolio companies.
Future endeavours to improve sustainability
Building upon these achievements, SGD Pharma has set its targets for the 2024 year ahead:
- 100% of sites to achieve environmental and energy management certification by 2025
- Zero severe accidents at every plant by 2025
- Deploy the French gender equality index across all locations
- Plant 10,000 mangrove trees in China during 2024
CEO of SGD Pharma, Olivier Rousseau explained: “We are proud of the company’s ongoing improvements in CSR, but there's a long investment ahead, which is why we are long-committed to the UN Global Compact: The ten principles of the UN Global Compact. This includes human rights, the environment and anti-corruption. These policies have guided our CSR strategy and helped us ensure that our company-wide policies meet the highest environmental, social and governance standards.”
Over the last year, SGD Pharma has also made significant progress in its mission to reduce its carbon emissions.
Working with the Science Based Targets Initiative (SBTi), the company has set the goal of reducing emissions by 35% in 2030 and by 65% in 2040, in line with SBTi’s 1.5 °C trajectory.
